Overview

* Compass Pathways ( CMPS ) Q2 operating income beats analyst expectations, driven by warrant liabilities

* Net loss for Q2 2025 was $38.4 mln, slightly higher than last year

* Cash position of $221.9 million at June 30, 2025; cash runway into 2027

Outlook

* COMPASS expects 26-week data from COMP006 trial in H2 2026

* Cash position expected to fund operations into 2027

* Annual cash outflow from operations expected at $120 mln to $145 mln

Result Drivers

* WARRANT LIABILITY IMPACT - Net loss driven by non-cash loss on fair value adjustment related to warrant liabilities

* R&D EXPENSES - Increase in expenses due to advancement of late-stage COMP360 Phase 3 clinical trials

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS -$0.41

Q2 Net -$38.40

Income mln

Q2 Beat -$42.93 -$45.50

Operatin mln mln (9

g Income Analysts

)

Q2 $42.93

Operatin mln

g

Expenses

Q2 -$38.27

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Compass Pathways PLC ( CMPS ) is $12.00, about 67.2% above its July 30 closing price of $3.94

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)